ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023 07:00 ET
|
ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Development of Axiomer® RNA base editing technology platform...
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023 08:00 ET
|
ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early...
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 22, 2022 06:15 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...